Evidence map›Paper›PMID 30333006›Full record

ArticleBMC cancer2018

Age-related sarcoma patient experience: results from a national survey in England.

Eugenie Younger, Olga Husson, Lindsey Bennister, Jeremy Whelan, Roger Wilson, Andy Roast, Robin L Jones, Winette Ta van der Graaf

Abstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Observational
  5. Article
  6. Assessing Sarcoma Awareness Among the General Population in Minnesota: A Cross-Sectional Survey Study from the Minnesota State Fair in 2015 and 2022.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eugenie YoungerSarcoma Unit, Royal Marsden Hospital, London, SW3 6JJ, UK.
Olga HussonSarcoma Unit, Royal Marsden Hospital, London, SW3 6JJ, UK.
Lindsey BennisterSarcoma UK Registered Cancer Charity, London, N1 6AH, UK.
Jeremy WhelanUniversity College London Hospital (UCLH), London, NW1 2BU, UK.
Roger WilsonSarcoma UK Registered Cancer Charity, London, N1 6AH, UK.
Andy RoastSarcoma UK Registered Cancer Charity, London, N1 6AH, UK.
Robin L JonesSarcoma Unit, Royal Marsden Hospital, London, SW3 6JJ, UK.
Winette Ta van der GraafSarcoma Unit, Royal Marsden Hospital, London, SW3 6JJ, UK. winette.vandergraaf@icr.ac.uk.ORCID http://orcid.org/0000-0001-7549-3338

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSarcomas are rare, heterogeneous tumours affecting patients of any age. Previous surveys describe that sarcoma patients report a significantly worse experience than those with common cancers. Consequently, Sarcoma UK conducted a national survey and these data were examined for age- and tumour-related differences in patients' experiences.

methodsPatients were randomly selected from respondents to National Cancer Patient Experience Surveys (n = 900). Differences between patient groups according to age (Adolescents and Young Adults [AYA] 18-39 years, middle-aged 40-64 years, elderly 65 + years) and tumour type (soft-tissue [STS] vs. bone]) were analysed with t-tests or chi-square tests.

resultsSurvey response rate was 62% (n = 558; STS 75%, bone sarcoma 25%). Delay in diagnosis was reported; 27% patients (n = 150) waited > 3 months and initial symptoms were incorrectly interpreted; AYA STS patients were significantly more likely to be treated for another condition, or advised that their symptoms were not serious, than older STS patients. Clinical trial participation was low (6%, n = 35). Symptom burden was high, most commonly daytime fatigue (48%, n = 277) and pain (44%, n = 248). AYAs were significantly more likely to report most side-effects and post-treatment concerns than older patients. Elderly patients were more satisfied with the information and emotional support provided than younger patients, however were significantly less likely to be referred to rehabilitation services.

conclusionsThis study identifies significant age-related differences in the sarcoma patient journey, which are not only related to variation in tumour-types. These results provide rationale for adopting an age-specific approach to the management of sarcoma patients in order to improve overall patient experience.

Indexed as

Surveys and QuestionnairesAdolescentAdultAgedAged, 80 and overAge FactorsCross-Sectional StudiesEnglandFemaleFollow-Up StudiesHumansMaleMiddle AgedOsteosarcomaSarcomaSoft Tissue NeoplasmsAdolescents and young adultsAge-relatedElderlyPatient experienceSarcoma

Identifiers

PMID30333006
PMCPMC6192120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.